Radiation Oncology Consulting

  • Home
  • Radiation Oncology Consulting

Radiation Oncology Consulting Radiation Oncology Consulting LLC offers education, auditing reviews, and interim management.

01/01/2023
Thank you for a wonderful birthday lunch
19/09/2022

Thank you for a wonderful birthday lunch

What a great birthday!
02/09/2022

What a great birthday!

The last time I saw her was July 6 I just can’t believe she’s gone
17/08/2022

The last time I saw her was July 6 I just can’t believe she’s gone

This was the last time that I saw Malin on July 6 I still can’t believe she’s gone
17/08/2022

This was the last time that I saw Malin on July 6 I still can’t believe she’s gone

September 9, 2021 ASTRO Advocates Against Proposed Radiation Oncology Cuts Set for January 1, 2022  Today, ASTRO submitt...
09/09/2021

September 9, 2021

ASTRO Advocates Against Proposed Radiation Oncology Cuts Set for January 1, 2022

Today, ASTRO submitted official comment letters to the Centers for Medicare and Medicaid Services (CMS) in response to the 2022 Medicare Physician Fee Schedule (MPFS) proposed rule, as well as needed changes to the Radiation Oncology Alternative Payment Model (RO Model), as found in the 2022 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule. Due to the proposed actions in both rules, radiation oncology cancer treatment services would experience $300 million in reductions effective January 1, 2022. Roughly half of the $300 million in cuts stem from the RO Model, while the rest are caused by proposed changes to the 2022 MPFS. ASTRO has provided an executive summary of the two comment letters.

ASTRO is very concerned about the financial implications that both proposals will have on access to care for cancer patients and the viability of radiation oncology practices, particularly those practices that serve rural and disadvantaged communities. In addition to comment letters, ASTRO issued an official statement and launched an advertising campaign to urge the Biden Administration to take action against these significant reductions. Please amplify these messages via your social media accounts by quote retweeting ASTRO’s tweets on the topic and tagging the President (), HHS ( or ), CMS ( or ) and your members of Congress.

ASTRO anticipates that final rules will be issued in November. During the interim, ASTRO will continue to advocate for changes to these proposals through continued engagement with CMS, as well as with members of Congress and the Biden Administration. ASTRO already has met with senior officials at the White House and Health and Human Services Department, as well as congressional health care leaders, with more meetings planned. ASTRO also is working closely with radiation oncology stakeholder organizations on a unified advocacy strategy to combat the cuts.

AMERICAN SOCIETY FOR RADIATION ONCOLOGY
251 18TH STREET SOUTH • 8TH FLOOR • ARLINGTON, VA • 703-502-1550
www.astro.orgwww.rtanswers.org

RO Model Start Date Delayed!Late Wednesday, October 21st, CMS announced that the implementation of the RO Model APM that...
23/10/2020

RO Model Start Date Delayed!

Late Wednesday, October 21st, CMS announced that the implementation of the RO Model APM that was scheduled to begin January 1, 2021 has been pushed back to July 1, 2021. PLEASE CONTINUE TO GIVE YOUR FEEDBACK TO CMS!!!!

You can visit the CMS RO Model website for RO Model information:
https://innovation.cms.gov/innovation-models/radiation-oncology-model

UPDATE: (10/21/2020) - CMS has received feedback from a number of stakeholders about the challenges of preparing to implement the RO Model by January 1, 2021. Based on this feedback, CMS intends to delay the RO Model start date to July 1, 2021. We are pursuing rulemaking to make this change.

https://www.justice.gov/opa/pr/former-cancer-center-president-indicted-participation-long-running-antitrust-conspiracyFo...
26/09/2020

https://www.justice.gov/opa/pr/former-cancer-center-president-indicted-participation-long-running-antitrust-conspiracy
Former Cancer Center President Indicted For Participation In Long-Running Antitrust Conspiracy
A federal grand jury returned an indictment against Dr. William Harwin, founder and former President of Florida Cancer Specialists & Research Institute LLC (FCS), for conspiring to allocate medical and radiation oncology treatments for patients in Southwest Florida, the Department of Justice announced today.
Department of Justice
Office of Public Affairs
The indictment, filed in the U.S. District Court in Fort Myers, Florida, charges Harwin for participating in a criminal conspiracy with a competing oncology group in Collier, Lee, and Charlotte counties (Southwest Florida). Beginning as early as 1999 and continuing until at least 2016, Harwin and his co-conspirators entered into an illegal agreement to allocate medical oncology treatments, such as chemotherapy, to FCS and radiation oncology treatments to a competing oncology group. The conspiracy allowed FCS and the competing oncology group to operate with minimal competition in Southwest Florida and limited valuable integrated care options and choices for cancer patients.
“As the charge demonstrates, the division remains committed to holding culpable executives accountable for their crimes, especially when they impact vulnerable Americans, such as those in need of life-saving treatments,” said Assistant Attorney General Makan Delrahim of the Department of Justice’s Antitrust Division. “The Antitrust Division will continue to work to protect competition and integrity in the healthcare industry.”
“It is unconscionable for a doctor to prioritize profits over patient care," said Michael F. McPherson, Special Agent in Charge of the FBI Tampa Field Office. “The FBI will persist in exposing unscrupulous medical providers who deny the public access to a competitive healthcare marketplace.”
The indictment follows a felony charge filed against FCS in April 2020 for its role in the same conspiracy in which Harwin is alleged to have participated. The Antitrust Division and FCS resolved the charge with a deferred prosecution agreement, under which the company admitted to conspiring to allocate treatments for cancer patients and agreed to pay a $100 million criminal penalty. FCS also agreed to waive and refrain from enforcing any non-compete provisions with its current or former oncologists or other employees who, during the term of the deferred prosecution agreement, open or join an oncology practice in Southwest Florida.
An indictment merely alleges that a crime has been committed, and all defendants are presumed innocent until proven guilty beyond a reasonable doubt.
The charge in the indictment carries a maximum penalty of 10 years in prison and a $1 million fine for individuals. The maximum fine may be increased to twice the gain derived from the crime or twice the loss suffered by victims if either amount is greater than $1 million.
Today’s announcement is the result of an ongoing federal antitrust investigation into market allocation and other anticompetitive conduct in the oncology industry, which is being conducted by the Antitrust Division’s Washington Criminal II Section and the FBI’s Tampa Field Office – Fort Myers R.A. Anyone with information in connection with this investigation or anticompetitive conduct in the healthcare industry generally is urged to contact the Antitrust Division’s Citizen Complaint Center at 1-888-647-3258 or visit https://www.justice.gov/atr/contact/newcase.html.

Secure .gov websites use HTTPS A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

22/09/2020

CMS released on August 4th a nearly 11% cut to the Medicare physician fee schedule’s conversion factor. In 2021 the conversion factor will be $32.26 down from $36.09 in 2020.

CMS contributes this decrease due to the projected pay increases to E/M office visit codes (99202-99215). This is the first overhaul in 25 years.

However, this decrease will translate decrease in payment for many services.

Stay tuned; this is budget neutrality for you

The RO Modeling plan.  Looks concerning.https://innovation.cms.gov/innovation-models/radiation-oncology-model
18/09/2020

The RO Modeling plan. Looks concerning.

https://innovation.cms.gov/innovation-models/radiation-oncology-model

The Radiation Oncology (RO) Model aims to improve the quality of care for cancer patients receiving radiotherapy (RT) and move toward a simplified and predictable payment system. The RO Model tests whether bundled, prospective, site neutral, modality agnostic, episode-based payments to physician gro...

06/04/2020

Telehealth for AMA CPT 77427®?

With the advent of Covid-19 there has been much discussion of telehealth especially regarding the AMA CPT 77427® Physicians’ Clinical Management. Below is a link from CMS regarding the covered Telehealth CPT codes:
Covered Telehealth Services for PHE for the COVID-19 pandemic, effective March 1, 2020 (ZIP)
These temporary changes will ensure that patients have access to physicians and other providers while remaining safely at home. Radiation Oncology is a “different animal” then the rest of all medicine. Linear accelerators are not mobile, therefore, the patient must come to the hospital or clinic daily for their prescribed external beam treatment.
Although 77427 is a covered telehealth code temporarily due to the pandemic, one must use clinical judgement and common sense as to whether one uses this code as a telehealth code.
According to the AMA CPT ®, “Radiation treatment management requires and incudes a minimum of one examination of the patient by the physician for medical evaluation and management (e.g., assessment of the patient’s response to treatment, coordination of care and treatment, review of imaging and/or lab test results with documentation”) for the radiation treatment management service (77427).
Since the patient is coming daily for treatments at the treatment facility, where the physician (and the patient) is on site, it is difficult for me to comprehend why CPT 77427 code would be considered a telehealth code. Wouldn’t the physicians’ want to at least see the patient why they are present? I understand if it is a new patient or follow up to perform telehealth calls or telehealth video with the patient, as they are at their homes and should remain there until this Covid-19 is controlled, but it is difficult to understand when the patient is in the clinic for treatment, why the physician wouldn’t want to at least see the patient while both are present.
This code, in my opinion and using common sense should not be considered a telehealth code automatically just because CMS is stating it can be.

01/11/2019

Today, the Trump Administration and the Centers for Medicare & Medicaid Services (CMS) finalized major policy changes that implement key provisions of President Trump’s Executive Order on Protecting and Improving Medicare for Our Nation’s Seniors that will reduce clinical burden, ensure appropri...

06/09/2019

Mount Rainier sunset reflections

By Alan Howe

06/09/2019
26/08/2019

Kevin Ewalt and I will be presenting "The power of 300" on Tuesday, at 9:45 a.m.September 17th, 2019 at the SROA Annual Meeting in Chicago! Hope to see you there!

11/07/2019

The proposed Radiation Oncology (RO) Model is an innovative payment model that would, if finalized, improve the quality of care for cancer patients receiving radiotherapy treatment, and reduce provider burden by moving toward a simplified and predictable payment system. The aim of this Model, which would involve required participation, is to test whether prospective site neutral, episode-based payments to physician group practices (PGPs), hospital outpatient departments (HOPD), and freestanding radiation therapy centers for radiotherapy (RT) episodes of care would reduce Medicare expenditures while preserving or enhancing the quality of care for Medicare beneficiaries.

This fact sheet discusses major provisions of the proposed RO Model. The RO Model is included in the Medicare Program; Specialty Care Models to Improve Quality of Care and Reduce Expenditures Notice of Proposed Rule Making. The proposed rule (CMS 5527-P) can be downloaded from the Federal Register athttps://www.hhs.gov/sites/default/files/CMS-5527-P.pdf

Background

Since 2014, CMS has been exploring potential ways to test an episode-based payment model for RT services. In December 2015, Congress enacted the Patient Access and Medicare Protection Act, which required the Secretary of Health and Human Services to submit to Congress a report on “the development of an episodic alternative payment model” for RT services furnished in. The report, which is available on the Center for Medicare and Medicaid Innovation’s (Innovation Center) website, was provided to Congress in November 2017.[1] The report identified three key reasons why radiation therapy is ready for payment and service delivery reform: the lack of site neutrality for payments; incentives that encourage volume of services over the value of services; and coding and payment challenges.

Site Neutrality: Under Medicare Fee-For-Service (FFS), RT services furnished in a freestanding radiation therapy center are paid under the Medicare Physician Fee Schedule (PFS) at the non-facility rate including payment for the professional and technical aspects of the services. For RT services furnished in an outpatient department of a hospital, the facility services are paid under the Hospital Outpatient Prospective Payment System (OPPS) and the professional services are paid under the PFS. These payment systems determine payment rates for the same services in different ways, which creates site-of-service payment differentials. This difference in payment rate may incentivize Medicare providers and suppliers to deliver RT services in one setting over another, even though the actual treatment and care received by Medicare beneficiaries for a given modality is the same in both settings.

Aligning Payments to Quality and Value, Rather than Volume: Incentives built into the current payment system promote volume of services over the value of services provided. Under both the OPPS and the PFS, entities and physicians that furnish RT services are typically paid incrementally; the more services they provide, the more claims they can submit to Medicare for payment. These incentives are not always aligned with what is clinically appropriate for the beneficiary. For example, for some cancer types, stages, and beneficiary characteristics, a shorter course of RT treatment with more radiation per fraction may be clinically appropriate.

CMS Coding and Payment Challenges: CMS examined RT services and their corresponding fee-for-service codes as part of CMS’s misvalued codes initiative based on their high volume and increasing use of new technologies.[2] CMS determined that there are difficulties in coding and setting payment rates appropriately for RT services. These difficulties have led to changes to valuations for these services under the PFS (e.g., payment reductions) and coding complexity across both payment systems. The Patient Access and Medicare Protection Act also froze payment rates for certain RT delivery and related imaging services in 2017 and 2018 and excluded those same services from being considered under the misvalued codes initiative for that same period. Section 51009 of the Bipartisan Budget Act of 2018 extended these policies through 2019.

Model Design

The proposed RO Model would take significant steps towards making prospective, episode-based payments in a site-neutral manner for 17 different cancer types. The Model would further the Innovation Center’s efforts to test site-neutral models and to test patient-centered, physician-focused models that provide an opportunity for physicians to participate in an Advanced Alternative Payment Model (APM) under the Quality Payment Program (QPP.). The Model would also be expected to improve the beneficiary experience by rewarding high-quality, patient-centered care and would incentivize high-value RT that results in better patient outcomes.

The RO Model would require participation from RT providers and suppliers that furnish RT services within randomly selected Core Based Statistical Areas. Beneficiaries would still be able to receive care from any provider or supplier of their choice. Model participants treating beneficiaries with one of the included cancer types would receive prospective, episode-based payment amounts for RT services furnished during a 90-day episode of care, instead of regular Medicare FFS payments, throughout the model performance period.

Model episode payments would be split into a professional component (PC) payment, which is meant to represent payment for the included RT services that may only be furnished by a physician, and the technical component (TC) payment, which is meant to represent payment for the included RT services that are not furnished by a physician, including the provision of equipment, supplies, personnel, and costs related to RT services. This division reflects the fact that RT professional and technical services are sometimes furnished by separate providers or suppliers.

Participant-specific payment amounts would be determined based on proposed national base rates, trend factors, and adjustments for each participant’s case-mix, historical experience, and geographic location. CMS would further adjust payment amounts by applying a discount factor. The discount factor, or the set percentage by which CMS reduces an episode payment amount, would reserve savings for Medicare and reduce beneficiary cost-sharing. The discount factor for the PC would be 4%, and the discount factor for the TC would be 5%. The payment amount would also be prospectively adjusted for withholds for incomplete episodes (2% for PC and TC), quality (2% for PC), and beneficiary experience (1% for TC starting in 2022). RO participants would have the ability to earn back a portion of the quality and patient experience withholds based on clinical data reporting, quality measure reporting and performance, and the beneficiary-reported Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Cancer Care Radiation Therapy Survey[3]. The standard beneficiary coinsurance and sequestration requirements would remain in effect.

Beneficiaries would still be responsible for the same cost-sharing requirement as under the traditional payment systems (i.e., typically 20% of the Medicare-approved amount for services), but because CMS would be applying a discount to each of these components, beneficiary cost-sharing may be, on average, lower relative to what typically would be paid under traditional Medicare FFS.

The Model design would encourage RO participants to furnish high quality patient-centered care. CMS would assess RO participants’ performance on measures of quality and patient experience and tie those assessments to payment. CMS would require certain RO participants to submit key clinical data that can be used for additional research, improvements to pricing, and the development of new quality measures specific to RT.

Quality Payment Program

The RO Model would be an Advanced APM and a Merit-based Incentive Payment System (MIPS) APM for the Quality Payment Program[4]. The RO Model would require RO participants to annually certify their intent to use of Certified Electronic Health Record Technology, include quality measure performance as a factor when determining payments, and require RO participants to bear more than a nominal amount of financial risk. RO participants who are APM Entities and eligible clinicians seeking Qualifying APM Participant (QP) status in an Advanced APM must comply with all RO Model requirements in order to be eligible for Advanced APM incentive payments. Participants who do not meet the QP threshold would not qualify for the APM incentive payment and instead would be in a MIPS APM.

For more information, visit: https://innovation.cms.gov/initiatives/radiation-oncology-model/

# # #
Get CMS news at cms.gov/newsroom, sign up for CMS news via email and follow CMS on Twitter CMS Administrator , , and .


[1]https://innovation.cms.gov/Files/reports/radiationtherapy-apm-rtc.pdf

[2] Section 1848(c)(2)(K) of the Social Security Act. Under the misvalued coding initiative, CMS reviews the resource inputs for several hundred codes annually.

[3] CAHPS®, which stands for Consumer Assessment of Healthcare Providers and Systems,1 is a registered trademark of the Agency for Healthcare Research and Quality.

[4] See the CY 2018 QPP final rule (82 FR 53568).

PreviousNext
Related Releases
Kidney Care First (KCF) and Comprehensive Kidney Care Contracting (CKCC) Models
Jul 10, 2019
Proposed End-Stage Renal Disease Treatment Choices (ETC) Mandatory Model
Jul 10, 2019
HHS To Transform Care Delivery for Patients with Chronic Kidney Disease
Jul 10, 2019
Programs of All-Inclusive Care for the Elderly (PACE) Final Rule (CMS-4168-F)
May 28, 2019
CMS Modernizes Care for Frail, Elderly Individuals Enrolled in PACE
May 28, 2019
Contact us
CMS News and Media Group

Johnathan Monroe, Director

Kelly Ceballos, Deputy Director

press@cms.hhs.gov
202-690-6145

Get email updates

Address


Alerts

Be the first to know and let us send you an email when Radiation Oncology Consulting posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Radiation Oncology Consulting:

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram